Lyra Therapeutics (LYRA) Other Gross PP&E Adjustments (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Other Gross PP&E Adjustments for 5 consecutive years, with -$12.0 million as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 19.81% to -$12.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$12.0 million, a 19.81% increase, with the full-year FY2024 number at -$15.5 million, up 49.17% from a year prior.
- Other Gross PP&E Adjustments was -$12.0 million for Q3 2025 at Lyra Therapeutics, up from -$12.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $7.0 million in Q2 2022 to a low of -$45.6 million in Q1 2024.
- A 5-year average of -$6.6 million and a median of -$1.8 million in 2023 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 91.88% in 2022, then tumbled 2400.05% in 2024.
- Lyra Therapeutics' Other Gross PP&E Adjustments stood at $6.2 million in 2021, then plummeted by 53.08% to $2.9 million in 2022, then tumbled by 1148.67% to -$30.4 million in 2023, then skyrocketed by 49.17% to -$15.5 million in 2024, then rose by 22.31% to -$12.0 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Other Gross PP&E Adjustments are -$12.0 million (Q3 2025), -$12.9 million (Q2 2025), and -$13.6 million (Q1 2025).